2:25 pm – 3:15 pm 3/26/2015 Better Business Track: Externalizing Pharma R&D @ MassBio Annual Meeting 2015, Cambridge, MA, Sonesta Hotel, 3/26 – 3/27, 2015
Reporter: Aviva Lev-Ari, PhD, RN
Dr. Aviva Lev-Ari will be in attendance on March 26, 2015, 8:00AM to March 27, 2015, 2:00PM
Leaders in Pharmaceutical Business Intelligence are Covering the Event in REALTIME using Social Media
http://pharmaceuticalintelligence.com
#pharma#investment#outsourcing
#pharmanews |
@MassBio@PharmaNews@Roche
@JNJInnovation @Baxter |
Panelists:
- Ashish Dugar, Head, External Development Group, Roche
Building the pipeline by resources: Roche NY, Washington DC,
Same company many have centers that capacity constrained other are Capital constrains, some may have both
Partnership can challenge internal bias, critique by a partner is fruitful and productive
Large pipeline is good
ARC – Academic Research Collaborations is very active
- Thomas Luby, Senior Director of New Ventures , Johnson & Johnson Innovation
Cambridge is the hub for talent, who does what and influence collaboration, a venture in a Biotech Center
Internalization comes first then externalization
Capacity to invest at difference Capital cycles
MA becomes Pharma like but Biotech spirit will continue to drive
Oncology needs a payment revolution to be viable as healthcare costs
- John Orloff, Global Head of Research and Development, Baxter BioSciences
Office in Cambridge and Vienna
Partnership can lead to lost of control
Partnership on Clinical Operation for externalization
- Jonathan Gertler
Transition from Academia, start ups,
Corporate commitment is very importance, small companies are more vulnerable than larger
Drivers for success: IP, best resources are not integrate-able, thus externalization will persist
Academic Freedom can be impacted by Collaboration
Moderator:
- Tacye Connolly, Owner, RRG, A VCLS Company
Leave a Reply